Patients
| Country | Value | Year |
|---|---|---|
| Iraq | 48.1 | 2019 |
| Jordan | 37.7 | 2019 |
| Lebanon | 38.1 | 2019 |
| Palestine | 39.1 | 2019 |
| Qatar | 40.9 | 2019 |
| Saudi Arabia | 34.0 | 2019 |
| Syria | 41.1 | 2019 |
| UAE | 41.4 | 2019 |
| Yemen | 29.3 | 2019 |
Updated
Reviewed by Vidhi Upadhyay
Middle East Renal Denervation Market Industry Trends and Forecast to 2034: Segmented by (Technology, Product, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$167.4 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $19.5 Mn | — | — |
| 2025 (base) | $24.5 Mn | +$5.0 Mn | — |
| 2026 (forecast) | $30.8 Mn | +$6.3 Mn | +25.7% |
| 2027 (forecast) | $38.7 Mn | +$7.9 Mn | +58% |
| 2028 (forecast) | $48.6 Mn | +$9.9 Mn | +98.6% |
| 2029 (forecast) | $61.1 Mn | +$12.5 Mn | +149.7% |
| 2030 (forecast) | $76.9 Mn | +$15.7 Mn | +213.8% |
| 2031 (forecast) | $96.6 Mn | +$19.8 Mn | +294.5% |
| 2032 (forecast) | $121.4 Mn | +$24.8 Mn | +395.8% |
| 2033 (forecast) | $152.6 Mn | +$31.2 Mn | +523.3% |
| 2034 (forecast) | $191.9 Mn | +$39.2 Mn | +683.5% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $24.5 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $191.9 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 25.7% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Technology, product and end user (see all) |
| Key players | Medtronic, Recor Medical (Otsuka), Boston Scientific Corporation, SoniVie, Ablative Solutions (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Renal denervation uses energy delivered through a catheter to calm nerves near the kidneys and lower hard-to-control high blood pressure.
Key segments of the renal Denervation market include technology (Radiofrequency, Ultrasound and Chemical) and product (Catheters and Generators).
Heart disease remains the leading cause of death worldwide. An ageing population, more minimally invasive procedures and strong clinical evidence for newer devices are driving the renal Denervation market.
Less invasive procedures, remote monitoring of implanted devices and rising access to cardiac care in emerging markets give the renal Denervation market room to grow.
High device prices, the need for trained specialists, reimbursement pressure and product recalls hold back the renal Denervation market.
The renal Denervation market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In some of the countries we cover here, medical devices are regulated by SFDA (Saudi Arabia)[1] and EDE (UAE)[2]. How care is paid for in some of these countries: free public care and CHI-regulated insurance (Saudi Arabia)[3] and mandatory health insurance (UAE)[4].
[1] Saudi Food and Drug Authority. Checked 14 Nov 2026.
[2] Emirates Drug Establishment. Checked 14 Nov 2026.
[3] Council of Health Insurance. Checked 14 Nov 2026.
[4] Ministry of Human Resources and Emiratisation. Checked 14 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how renal Denervation products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Middle East.
What doctors and scientists are doing in Renal Denervation right now, from free public sources.
| Country | Value | Year |
|---|---|---|
| Iraq | 48.1 | 2019 |
| Jordan | 37.7 | 2019 |
| Lebanon | 38.1 | 2019 |
| Palestine | 39.1 | 2019 |
| Qatar | 40.9 | 2019 |
| Saudi Arabia | 34.0 | 2019 |
| Syria | 41.1 | 2019 |
| UAE | 41.4 | 2019 |
| Yemen | 29.3 | 2019 |
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Middle East · 2 shared keywords
Middle East · 2 shared keywords
Middle East · 1 shared keyword
Middle East · 1 shared keyword
Middle East
Middle East
Digital Health · Middle East
Pharmaceuticals · Middle East
Pharmaceuticals · Middle East
Pharmaceuticals · Middle East
Pharmaceuticals · Middle East
Healthcare Services · Middle East